IONM Evidence & Literature

This landmark large-database study analyzed over 50,000 patients to conduct one of the first formal cost-utility analyses of IONM in spine surgery. The most striking finding: neurological deficit rates were 4.1% without IONM versus just 0.3% with IONM — a more than tenfold reduction. Using a Markov model with 5,000-iteration probabilistic sensitivity analysis, IOM was cost-effective from a health system perspective (ICER $60,734/QALY — well below the U.S. $100,000 willingness-to-pay threshold) and dominant from a societal perspective, meaning better patient outcomes at lower overall cost. In 74% of model simulations, IONM remained cost-effective.

Timely intraoperative response to MEP alerts directly prevents neurologic injury — demonstrating IONM's life-altering impact for pediatric patients. This retrospective consecutive case study analyzed 513 pediatric spine surgeries to directly test whether surgical interventions triggered by MEP alerts change outcomes. The gradient of risk was unambiguous: zero motor deficits when no MEP changes occurred; 2.8% deficit rate (root lesions only) with reversible changes; and 36.8% with irreversible changes. Critically, surgical interventions in response to MEP alerts significantly reduced postoperative deficits compared to nonsurgical interventions alone (p=0.0216) — providing direct evidence that MEP-triggered intervention changes outcomes, not merely documents injury.

This landmark retrospective study from Duke University compared auditory outcomes in 152 unmonitored versus 70 BAEP-monitored posterior fossa microvascular decompression surgeries — all performed by a single surgeon using identical technique, isolating monitoring as the sole variable. Zero monitored patients suffered profound hearing loss, compared to 6.6% in the unmonitored group (p=0.02). Surgeon experience was explicitly controlled: the unmonitored group showed no improvement in complication rates over time, ruling out learning curve as an explanation. This was the first study ever to demonstrate a statistically significant reduction in operative morbidity directly attributable to intraoperative evoked potential monitoring.

SSEP monitoring accurately identifies patients at risk of neurologic injury — supporting its use as a standard safety measure in cervical spine surgery. This comprehensive meta-analysis from the University of Pittsburgh pooled 23 studies and 7,747 patients. Patients with new postoperative neurological deficits were nearly 27 times more likely to have had significant intraoperative SSEP changes (DOR 27.32). Specificity was 96.7%, meaning the test is highly reliable when it fires. Irreversible SSEP changes were even more predictive, with a DOR of 167.90. The authors conclude that all significant SSEP changes warrant alarm, with irreversible changes and complete signal loss demanding the greatest clinical urgency.

This foundational paper established that intraoperative neuromonitoring (IONM) offers measurable value when evaluated through cost-effectiveness frameworks commonly used in healthcare policy. Ney and van der Goes reviewed cost-utility and cost-benefit models showing that IONM, though it adds modest upfront cost, reduces downstream expenses associated with neurologic complications, extended hospitalizations, and litigation. Their comparative-effectiveness modeling positioned IONM as a high-value safety technology consistent with modern value-based care standards. Using pooled sensitivity (94%) and specificity (96%) from the published literature, their model showed IONM saves approximately $23,189 per surgery from a societal lifetime perspective — and remains cost-saving whenever the neurological complication rate exceeds just 0.3%. IONM delivers measurable economic and clinical value — protecting patients and reducing overall system costs.

This foundational economic analysis from the University of Verona established a simple but powerful benchmark: preventing a single paraplegia offsets the cost of monitoring hundreds of procedures. Using National Spinal Cord Injury Statistical Center lifetime healthcare cost data, the authors showed that at a baseline paraplegia rate of just 0.1%, IOM is cost-neutral if per-case monitoring costs remain below $977 — well within the range of actual IONM reimbursement. For high tetraplegia, the ceiling rises to $2,924 per case. Even assuming rare neurologic injury rates (≈ 0.5–1%), preventing a single paraplegia offsets the cost of monitoring hundreds of procedures. The authors further concluded that randomized controlled trials withholding monitoring would be ethically unjustifiable given this evidence — and that court-awarded malpractice compensation for surgical paralysis makes the economic case for IONM even more compelling. Preventing one major neurologic injury easily outweighs the cumulative cost of monitoring thousands of patients.